DaVita price target lowered to $140 from $145 at BofA

BofA lowered the firm’s price target on DaVita (DVA) to $140 from $145 and keeps an Underperform rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.